Setting 
My Cart
Toggle Nav
mobile icon
Close
  • Menu
  • Setting

Signaling Pathways

Items 1621-1630 of 9367

Page
per page
  1. CH5183284 (Debio-1347)
    B4985 CH5183284 (Debio-1347)
    Summary: selective and orally available FGFR inhibitor
      ≥35.6 mg/mL
  2. LY2409881
    B4986 LY2409881
    Summary: potent and selective IKK2 inhibitor
      ≥59.4 mg/mL
  3. Liproxstatin-1
    B4987 Liproxstatin-1
     4 Citation
    Summary: A potent ferroptosis inhibitor
      insoluble in H2O; ≥10.5 mg/mL
  4. BRD73954
    B4988 BRD73954
     1 Citation
    Summary: potent and selective HDAC inhibitor
      ≥46.4 mg/mL
  5. EPZ015666
    B4989 EPZ015666
    Target: Protein Arginine Methyltransferases
    Summary: PRMT5 inhibitor
      insoluble in EtOH; insoluble in H2O; ≥19.17 mg/mL
  6. Purvalanol A
    B4990 Purvalanol A
    Summary: potent, and cell-permeable CDK inhibitor
      insoluble in EtOH; insoluble in H2O; ≥19.45 mg/mL
  7. GNE-317
    B4991 GNE-317
    Summary: potent, brain-penetrant PI3K inhibitor
      Soluble in DMSO
  8. ETC-1002
    A8710 ETC-1002
    Summary: ACL inhibitor and AMPK activator
      insoluble in H2O; ≥97.6 mg/mL
  9. DDD107498
    A8711 DDD107498
     5 Citation
    Target: Eukaryotic elongation factors
    Summary: A novelmultiple-stage antimalarial agent
      insoluble in H2O; ≥14.05 mg/mL
  10. Chk1 and MK2 Inhibitors set
    A9908 Chk1 and MK2 Inhibitors set
    Summary: Chk1- and MK2 inhibitors

Items 1621-1630 of 9367

Page
per page